Inhibitor Therapeutics, Inc. Royalty Expense
Inhibitor Therapeutics, Inc. (INTI) reported Royalty Expense of $10.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RoyaltyExpense · last filed 2026-03-26
- Inhibitor Therapeutics, Inc. royalty expense for fiscal 2025 was $10.00K, a 0.00% change from fiscal 2024.
- Inhibitor Therapeutics, Inc. royalty expense for fiscal 2024 was $10.00K.
- Inhibitor Therapeutics, Inc. royalty expense for fiscal 2022 was $50.00K.
| Period end | Royalty Expense | Royalty Expense 12 month |
|---|---|---|
| 2025-12-31 | $10.00K 10-K · filed 2026-03-26 | |
| 2024-12-31 | $10.00K 10-K · filed 2026-03-26 | |
| 2023-12-12 | $150.00K 10-Q · filed 2025-11-13 | |
| 2022-12-31 | $50.00K 10-K · filed 2026-03-26 |